BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 23051711)

  • 1. Monoclonal antibodies recognizing cross-neutralization epitopes in human papillomavirus 16 minor capsid protein L2.
    Nakao S; Mori S; Kondo K; Matsumoto K; Yoshikawa H; Kanda T
    Virology; 2012 Dec; 434(1):110-7. PubMed ID: 23051711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
    Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
    Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies.
    Rubio I; Seitz H; Canali E; Sehr P; Bolchi A; Tommasino M; Ottonello S; Müller M
    Virology; 2011 Jan; 409(2):348-59. PubMed ID: 21074234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes.
    Kondo K; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
    J Med Virol; 2008 May; 80(5):841-6. PubMed ID: 18360909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.
    Slupetzky K; Gambhira R; Culp TD; Shafti-Keramat S; Schellenbacher C; Christensen ND; Roden RB; Kirnbauer R
    Vaccine; 2007 Mar; 25(11):2001-10. PubMed ID: 17239496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A surface immunodeterminant of human papillomavirus type 16 minor capsid protein L2.
    Kawana K; Matsumoto K; Yoshikawa H; Taketani Y; Kawana T; Yoshiike K; Kanda T
    Virology; 1998 Jun; 245(2):353-9. PubMed ID: 9636375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20 -- 38) peptide displayed on bacterial thioredoxin.
    Rubio I; Bolchi A; Moretto N; Canali E; Gissmann L; Tommasino M; Müller M; Ottonello S
    Vaccine; 2009 Mar; 27(13):1949-56. PubMed ID: 19368776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6.
    Kawana K; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
    J Virol; 1999 Jul; 73(7):6188-90. PubMed ID: 10364381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
    Pouyanfard S; Spagnoli G; Bulli L; Balz K; Yang F; Odenwald C; Seitz H; Mariz FC; Bolchi A; Ottonello S; Müller M
    J Virol; 2018 Feb; 92(4):. PubMed ID: 29212932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2.
    Seitz H; Schmitt M; Böhmer G; Kopp-Schneider A; Müller M
    Int J Cancer; 2013 Feb; 132(3):E139-48. PubMed ID: 22961598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies.
    Kawana K; Kawana Y; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
    Vaccine; 2001 Jan; 19(11-12):1496-502. PubMed ID: 11163673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles.
    Culp TD; Spatz CM; Reed CA; Christensen ND
    Virology; 2007 May; 361(2):435-46. PubMed ID: 17222883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human papillomavirus type 16 minor capsid protein l2 N-terminal region containing a common neutralization epitope binds to the cell surface and enters the cytoplasm.
    Kawana Y; Kawana K; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
    J Virol; 2001 Mar; 75(5):2331-6. PubMed ID: 11160736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Establishment and application of human papillomavirus type 16 pseudovirions neutralization assay].
    Lu WX; Cheng T; Li SW; Pan HR; Shen WT; Chen YX; Zhang T; Zheng Z; Zhang J; Xia NS
    Sheng Wu Gong Cheng Xue Bao; 2006 Nov; 22(6):990-5. PubMed ID: 17168325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing.
    Tyler M; Tumban E; Dziduszko A; Ozbun MA; Peabody DS; Chackerian B
    Vaccine; 2014 Jul; 32(34):4267-74. PubMed ID: 24962748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting synthetic Human Papillomavirus (HPV) L2 disulfide-induced N-terminus conformational epitopes for pan-HPV vaccine development.
    Khanal S; Ferraris ED; Zahin M; Joh J; Ghim SJ; Jenson AB
    Exp Mol Pathol; 2015 Oct; 99(2):330-4. PubMed ID: 26134615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2.
    Alphs HH; Gambhira R; Karanam B; Roberts JN; Jagu S; Schiller JT; Zeng W; Jackson DC; Roden RB
    Proc Natl Acad Sci U S A; 2008 Apr; 105(15):5850-5. PubMed ID: 18413606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies.
    Wang JW; Jagu S; Wu WH; Viscidi RP; Macgregor-Das A; Fogel JM; Kwak K; Daayana S; Kitchener H; Stern PL; Gravitt PE; Trimble CL; Roden RB
    Clin Vaccine Immunol; 2015 Jul; 22(7):806-16. PubMed ID: 25972404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies.
    Combelas N; Saussereau E; Fleury MJ; Ribeiro T; Gaitan J; Duarte-Forero DF; Coursaget P; Touzé A
    J Transl Med; 2010 Mar; 8():28. PubMed ID: 20334659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A protective and broadly cross-neutralizing epitope of human papillomavirus L2.
    Gambhira R; Karanam B; Jagu S; Roberts JN; Buck CB; Bossis I; Alphs H; Culp T; Christensen ND; Roden RB
    J Virol; 2007 Dec; 81(24):13927-31. PubMed ID: 17928339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.